European Medicines Agency grants Orphan Drug Designation to Viralym-M for treatment of viral diseases and infections in patients undergoing hematopoietic stem cell transplantation

This allogeneic, multi-virus specific T-Cell therapy is being developed for treatment and prevention of disease caused by BK virus, cytomegalovirus, human herpes virus-6, Epstein Barr virus, adenovirus and JC virus. It has also been granted PRIority MEdicines (PRIME) designation.

Biospace Inc.